Skip to Content
Merck
CN

B7937

BSc3094 monohydrobromide

≥98% (HPLC)

Synonym(s):

2-[4-(4-Nitrophenyl)-2-thiazolyl]hydrazide-1H-benzimidazole-6-carboxylic acid monohydrobromide

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C17H12N6O3S·HBr
CAS Number:
1173021-98-1
Molecular Weight:
461.29
NACRES:
NA.25
PubChem Substance ID:
329773303
UNSPSC Code:
12352200
MDL number:
MFCD12912398
Assay:
≥98% (HPLC)
Form:
solid
Quality level:
100
Storage condition:
protect from light

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

InChI key

HVNYYJJWBWMGCO-UHFFFAOYSA-N

SMILES string

Br.[O-][N+](=O)c1ccc(cc1)-c2csc(NNC(=O)c3ccc4[nH]cnc4c3)n2

InChI

1S/C17H12N6O3S.BrH/c24-16(11-3-6-13-14(7-11)19-9-18-13)21-22-17-20-15(8-27-17)10-1-4-12(5-2-10)23(25)26;/h1-9H,(H,18,19)(H,20,22)(H,21,24);1H

assay

≥98% (HPLC)

form

solid

storage condition

protect from light

solubility

DMSO: 22 mg/mL

storage temp.

2-8°C

Quality Level

100

Application

BSc3094 is used in tau protein amyloidogenicity/tauopathy research to study the processes of tau aggregation and cross-linking in neurodegenerative disease development.

Biochem/physiol Actions

BSc3094 is a potent inhibitor of tau aggregation and dissolves preformed tau paired helical filaments. BSc3094 interacts closely with the tau protein at the edge involving protons I-IV, while the second attachment site seems to be at the nitro group. In N2A cells (model system for tau aggregation), BSc3094 exhibited low toxicity.
BSc3094 is a potent inhibitor of tau aggregation.

pictograms

Exclamation mark
GHS07

signalword

Warning

hcodes

H302,H319

Hazard Classifications

Acute Tox. 4 Oral - Eye Irrit. 2

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Faceshields, Gloves

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
019K4606V
019K4606

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

M Pickhardt et al.
Current Alzheimer research, 4(4), 397-402 (2007-10-03)
Cell models of tauopathy were generated in order to study mechanisms of neurodegeneration involving abnormal changes of tau. They are based on neuroblastoma cell lines (N2a) that inducibly express different forms of the repeat domain of tau (tau(RD)), e.g. the
Luc Buée et al.
Biochemical Society transactions, 38(4), 967-972 (2010-07-28)
Tau pathology is characterized by intracellular aggregates of abnormally and hyperphosphorylated tau proteins. It is encountered in many neurodegenerative disorders, but also in aging. These neurodegenerative disorders are referred to as tauopathies. Comparative biochemistry of the tau aggregates shows that
Chronis Fatouros et al.
Human molecular genetics, 21(16), 3587-3603 (2012-05-23)
Increased Tau protein amyloidogenicity has been causatively implicated in several neurodegenerative diseases, collectively called tauopathies. In pathological conditions, Tau becomes hyperphosphorylated and forms intracellular aggregates. The deletion of K280, which is a mutation that commonly appears in patients with frontotemporal

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service